RBC upgrades Sartorius on stronger outlook, AI opportunities

** RBC upgrades German pharmaceutical equipment supplier Sartorius SATG.DE to "outperform" from "sector perform", citing an improving outlook, accelerating growth prospects and potential benefits from AI-driven demand

** The broker points to the company's raised guidance, supported by favourable foreign exchange trends as well as expectations for faster underlying growth in 2027

** AI is emerging as a demand driver across biopharma and academia, with Sartorius set to benefit through its LPS division and small-scale bioreactor range, RBC says

** Out of four analysts covering the stock, one rates it "strong buy", two "buy" and one "hold" - LSEG data

($1 = 0.8919 euros)